A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.
暂无分享,去创建一个
C. Azzoli | P. Jänne | J. Neal | L. Sequist | A. Shaw | R. Heist | J. Temel | B. Goodgame | N. Pennell | M. Lanuti